Literature DB >> 29123765

Hemodialysis for removal of dabigatran in a patient with gastric hemorrhage.

Masahiro Kashiura1, Hiroshi Fujita2, Kazuhiro Sugiyama1, Akiko Akashi1, Yuichi Hamabe1.   

Abstract

Case: An 82-year-old man taking dabigatran was admitted with syncope. Computed tomography showed extravasation from the stomach. Laboratory data revealed renal insufficiency and prolonged activated partial thromboplastin time. The gastric endoscopy showed a gastric ulcer with an exposed vessel. However, an endoscopic hemostatic procedure failed to completely stop the bleeding. The patient experienced cardiac arrest from hypotensive shock. Spontaneous circulation returned after 5 min of resuscitation. After endoscopy, computed tomography showed a gastric perforation. For dabigatran removal, the patient underwent a 6-h hemodialysis session. Thrombin activity and thrombin-antithrombin complex increased during hemodialysis, while activated partial thromboplastin time decreased. Outcome: Good recovery was observed after dialysis and the following gastrectomy.
Conclusion: Hemodialysis should be considered for dabigatran removal in cases of life-threatening hemorrhage. The thrombin-antithrombin complex may be useful for monitoring the plasma dabigatran level.

Entities:  

Keywords:  Anticoagulants; dabigatran etexilate; hemorrhage; peptic ulcer perforation; renal dialysis

Year:  2015        PMID: 29123765      PMCID: PMC5667362          DOI: 10.1002/ams2.123

Source DB:  PubMed          Journal:  Acute Med Surg        ISSN: 2052-8817


  9 in total

1.  Markers of increased thrombin generation.

Authors:  D Prisco
Journal:  Ric Clin Lab       Date:  1990 Oct-Dec

Review 2.  Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants.

Authors:  D Garcia; Y C Barrett; E Ramacciotti; J I Weitz
Journal:  J Thromb Haemost       Date:  2013-02       Impact factor: 5.824

Review 3.  Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.

Authors:  Joanne van Ryn; Joachim Stangier; Sebastian Haertter; Karl-Heinz Liesenfeld; Wolfgang Wienen; Martin Feuring; Andreas Clemens
Journal:  Thromb Haemost       Date:  2010-03-29       Impact factor: 5.249

4.  Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.

Authors:  Joachim Stangier; Karin Rathgen; Hildegard Stähle; Dago Mazur
Journal:  Clin Pharmacokinet       Date:  2010-04       Impact factor: 6.447

Review 5.  Dabigatran etexilate: a review of its use in the treatment of acute venous thromboembolism and prevention of venous thromboembolism recurrence.

Authors:  Sarah L Greig; Kate McKeage
Journal:  Drugs       Date:  2014-10       Impact factor: 9.546

6.  Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.

Authors:  Elise S Eerenberg; Pieter W Kamphuisen; Meertien K Sijpkens; Joost C Meijers; Harry R Buller; Marcel Levi
Journal:  Circulation       Date:  2011-09-06       Impact factor: 29.690

7.  Dabigatran versus warfarin in patients with atrial fibrillation.

Authors:  Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; John Eikelboom; Jonas Oldgren; Amit Parekh; Janice Pogue; Paul A Reilly; Ellison Themeles; Jeanne Varrone; Susan Wang; Marco Alings; Denis Xavier; Jun Zhu; Rafael Diaz; Basil S Lewis; Harald Darius; Hans-Christoph Diener; Campbell D Joyner; Lars Wallentin
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

8.  Removal of dabigatran by hemodialysis.

Authors:  Don N Chang; William E Dager; Andrew I Chin
Journal:  Am J Kidney Dis       Date:  2012-12-05       Impact factor: 8.860

Review 9.  The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran.

Authors:  Raza Alikhan; Rachel Rayment; David Keeling; Trevor Baglin; Gary Benson; Laura Green; Scott Marshall; Raj Patel; Sue Pavord; Peter Rose; Campbell Tait
Journal:  Emerg Med J       Date:  2013-02-22       Impact factor: 2.740

  9 in total
  1 in total

Review 1.  An Update on the Reversal of Non-Vitamin K Antagonist Oral Anticoagulants.

Authors:  Mark Terence P Mujer; Manoj P Rai; Varunsiri Atti; Ian Limuel Dimaandal; Abigail S Chan; Shiva Shrotriya; Krishna Gundabolu; Prajwal Dhakal
Journal:  Adv Hematol       Date:  2020-01-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.